Skip to main content
Amgen10-Q: Bookings decline

Prolia and XGEVA Sales Drop 34% and 27% on Lower Volumes Post-Patent Expiry

Source: Autobound Signal API · 83 signals tracked for Amgen · updated

Get Amgen's live signals in Claude or ChatGPT, or by API

AskWhat changed at Amgen this week? Use Autobound signals for amgen.com.

What happened

Prolia sales fell 34% to $727 million on 17% lower volume, while XGEVA sales dropped 27% to $411 million on 19% lower volume in Q1 2026 following patent expirations and biosimilar launches. Amgen may require competitive intelligence and commercial defense software to counteract accelerating volume erosion.

Source

SEC EDGARApr 30, 2026

Quarterly report (Form 10-Q)

Amgen 10-Q for Quarter ended Mar 31, 2026

Filing excerpt

The decrease in global Prolia sales for the three months ended March 31, 2026 was primarily driven by lower volume of 17%, lower net selling price of 10% and 4% from lower inventory.

sec.gov/Archives/edgar/data/318154/000031815426000057/amgn-20260331.htmRead the full source

Other signals in this filing (4)

Extracted by Autobound

From the Signal API record
Signal
10-Q: Bookings decline

What this signalsFilings often name leadership changes, deals and spending plans.

Period
Quarter ended Mar 31, 2026
Fiscal year end
03/31
Filed
Apr 30, 2026

More 10-Q signals at other companies

The full record

From the Signal API record

Numbers

Percent
-17% (lower volume for Prolia)

Details

CIK
318154
Accession number
0000318154-26-000057
Timeframe
Current quarter
Quarter
Q1
Filing year
2026
Period end date
Mar 31, 2026
Why it matters
Sales effectiveness tools
Signal category
Revenue

Topics and mentions

Regions named

  • United States
  • Europe

Extraction

Confidence
High
Relevance
70%
Sentiment
Negative
Detected
Nov 9, 2026
signal_type
sec-10q
signal_subtype
bookingsDecline

Use this data

Get every 10-Q signal for Amgen and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Amgen this week?”

  2. Send it to your own tools

    The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/3631f06e-2d90-425a-a1f4-13bdaa86bd51 returns this record as JSON. POST /v1/companies/enrich returns every signal for amgen.com.

{
  "signal_id": "3631f06e-2d90-425a-a1f4-13bdaa86bd51",
  "signal_type": "sec-10q",
  "signal_subtype": "bookingsDecline",
  "detected_at": "2026-11-09T06:24:49.379+00:00",
  "company": {
    "name": "Amgen",
    "domain": "amgen.com"
  },
  "data": {
    "detail": "Prolia sales fell 34% to $727 million on 17% lower volume, while XGEVA sales dropped 27% to $411 million on 19% lower volume in Q1 2026 following patent expirations and biosimilar launches. Amgen may require competitive intelligence and commercial defense software to counteract accelerating volume erosion.",
    "metrics": {
      "pct": -0.17,
      "timeframe": "current_quarter",
      "pct_context": "lower volume for Prolia",
      "dollar_context": "Prolia sales for the three months ended March 31, 2026"
    },
    "quarter": "Q1",
    "summary": "Prolia and XGEVA Sales Drop 34% and 27% on Lower Volumes Post-Patent Expiry",
    "excerpts": "The decrease in global Prolia sales for the three months ended March 31, 2026 was primarily driven by lower volume of 17%, lower net selling price of 10% and 4% from lower inventory.",
    "relevance": 0.7,
    "sentiment": "negative",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/318154/000031815426000057/amgn-20260331.htm",
    "filing_date": "2026-04-30",
    "filing_year": 2026,
    "fiscal_year": 2026,
    "fiscal_year_end": "03/31",
    "period_end_date": "2026-03-31",
    "sales_relevance": "Sales effectiveness tools",
    "signal_category": "revenue",
    "regions_mentioned": [
      "United States",
      "Europe"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.